Wanbury reports explosive Q3 profit surge, signals strong growth ahead
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Novo Medi Sciences aims to reach millions nationwide and provide NEXIPOX PLUS vaccination against chickenpox to thousands of underprivileged girl children
Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility
Subscribe To Our Newsletter & Stay Updated